Lymphoproliferative Disorders clinical trials at UC Irvine

• Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies

  open to eligible people ages 18 years and up

  A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory EBV+ lymphomas.

  Orange, California and other locations

Last updated: November 3, 2020